Lo Castro Flavia, Guerzoni Simona, Pellesi Lanfranco
Medical Toxicology, Headache and Drug Abuse Research Center, Department of Specialized Medicine, AOU Policlinico di Modena, Modena, Italy.
Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Drug Healthc Patient Saf. 2021 Nov 23;13:233-240. doi: 10.2147/DHPS.S304373. eCollection 2021.
The treatment of migraine is often complicated by insufficient headache relief, a miscellany of side effects and the risk of developing Medication Overuse Headache (MOH). Novel acute therapies have been recently developed and are now in the early post-marketing phase. Lasmiditan is a highly selective serotonin receptor agonist that binds to the 5-HT receptor, while ubrogepant and rimegepant antagonize the calcitonin gene-related peptide receptor. All three medications are now prescribed in a real-world setting, and an adequate level of knowledge is the starting point for rational use. In this rapid systematic review, we have established what is known about lasmiditan, ubrogepant and rimegepant, highlighting the most relevant safety aspects available from published studies and speculating about their risk of MOH.
偏头痛的治疗常常因头痛缓解不足、一系列副作用以及发生药物过度使用性头痛（MOH）的风险而变得复杂。新型急性疗法最近已研发出来，目前正处于上市后早期阶段。拉米地坦是一种高度选择性的血清素受体激动剂，可与5-HT受体结合，而ubrogepant和瑞美吉泮则拮抗降钙素基因相关肽受体。这三种药物目前都在实际临床中使用，而足够的知识水平是合理使用的起点。在这项快速系统评价中，我们梳理了关于拉米地坦、ubrogepant和瑞美吉泮的已知信息，突出了已发表研究中最相关的安全性方面，并推测了它们发生MOH的风险。
